Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI

Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI

EGFR-mutant non-small cell lung cancer (NSCLC) is a common type of lung cancer, with EGFR tyrosine kinase inhibitors (EGFR-TKIs) being the standard first-line treatment. However, most patients with NSCLC eventually develop resistance to EGFR-TKIs. Studies on the mechanism underlying EGFR-TKI resista...

Full description

Saved in:
Bibliographic Details
Main Authors: Yiming ZENG, Wenfeng FANG, Li ZHANG
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2025-06-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
egfr-mutant nsclc
egfr-tki resistance
targeted therapy
immunotherapy
novel drugs
Online Access:http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1209
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items